- Home »
- Quarterly Results »
- Shukra Pharmaceuticals Q1 Results Revenue Drops Significantly to ₹317.80 Lakhs, Net Profit Decreases to ₹48.53 Lakhs
Shukra Pharmaceuticals Q1 Results Revenue Drops Significantly to ₹317.80 Lakhs, Net Profit Decreases to ₹48.53 Lakhs
Shukra Pharmaceuticals Q1 Results show a 71.76% QoQ decline in revenue from operations to ₹317.80 lakhs, while Shukra Pharmaceuticals Q1 Results also reflect an 87.8% YoY drop in net profit to ₹48.53 lakhs.
by Madhumitha
Updated Sep 04, 2024
Table of Content
Shukra Pharmaceuticals Q1 Results 2024-2025: Shukra Pharmaceuticals released their Q1 results for the fiscal year 2024-2025 on August 12, 2024. The company reported revenue from operations of ₹317.80 lakhs for the quarter ended June 30, 2024, marking a 71.76% decrease compared to ₹1,088.39 lakhs in the previous quarter.
YOY, this represents a 71.71% decline from the ₹1,126.92 lakhs reported for Q1 of the previous fiscal year. This significant decrease reflects the ongoing challenges in the pharmaceutical sector and the impact of shifting market dynamics.
On a positive note, Shukra Pharmaceuticals managed to achieve a net profit of ₹48.53 lakhs for the quarter, contrasting sharply with the ₹398.59 lakhs net profit in the previous quarter, an 87.8% quarter-over-quarter drop.
YOY, the company experienced a substantial 87.8% reduction from the ₹398.59 lakhs reported in Q1 of the previous fiscal year. Despite these challenges, the company's efforts to manage costs and streamline operations have resulted in a stable financial position relative to the broader industry downturn.
For More Q1 results check our Twitter Page.
Shukra Pharmaceuticals Q1 Results 2024-2025
Here is a table of Shukra Pharmaceuticals's Q1 results for the fiscal year 2024-2025:
| Particulars | Quarter Ended 30th June 2024 | Quarter Ended 31st March 2024 |
|---|---|---|
| Revenue from Operations | ₹317.80 lakhs | ₹1,088.39 lakhs |
| Net Profit/(Loss) | ₹48.53 lakhs | ₹398.59 lakhs |
| Earnings per Share (Basic) | ₹0.11 | ₹3.64 |
| Earnings per Share (Diluted) | ₹0.11 | ₹3.64 |
| Total Income from Operations | ₹389.56 lakhs | ₹1,226.07 lakhs |
| Total Expenses | ₹309.89 lakhs | ₹703.72 lakhs |
| Profit/(Loss) Before Tax | ₹79.67 lakhs | ₹522.35 lakhs |
| Tax Expenses | ₹26.60 lakhs | ₹48.53 lakhs |
Source: Click Here
Shukra Pharmaceuticals Current Market Overview
Shukra Pharmaceuticals is currently valued at ₹286 crore in the market, with its shares trading at ₹65.3 each. The stock has seen a high of ₹130 and a low of ₹20.4 in the past year. It has a price-to-earnings ratio of 15.3, indicating how much investors are willing to pay for each unit of earnings.
The company's book value stands at ₹13.2 per share, and it offers a dividend yield of 0.18%. Shukra Pharmaceuticals boasts strong profitability metrics, with a return on capital employed (ROCE) of 44.2% and a return on equity (ROE) of 44.7%, reflecting good financial health and effective use of its resources.
| Metric | Value |
|---|---|
| Market Cap | ₹286 Cr |
| Current Price | ₹65.3 |
| High / Low (Past Year) | ₹130 / ₹20.4 |
| Stock P/E | 15.3 |
| Book Value | ₹13.2 |
| Dividend Yield | 0.18% |
| ROCE | 44.2% |
| ROE | 44.7% |
| Face Value | ₹10.0 |
Q1 Results
Here are Shukra Pharmaceuticals's financial results for Q4 FY 2023-2024 and Q1 FY 2024-2025:
| Particulars | Dec 2023 (₹ Cr) | Mar 2024 (₹ Cr) | Jun 2024 (₹ Cr) |
|---|---|---|---|
| Sales | 18.89 | 10.88 | 3.18 |
| Expenses | 9.34 | 6.45 | 2.38 |
| Operating Profit | 9.55 | 4.43 | 0.80 |
| OPM % | 50.56% | 40.72% | 25.16% |
| Other Income | 0.56 | 1.38 | 0.72 |
| Interest | 0.07 | 0.07 | 0.06 |
| Depreciation | 0.51 | 0.52 | 0.67 |
| Profit Before Tax | 9.53 | 5.22 | 0.79 |
| Tax % | 1.05% | 23.75% | 40.51% |
| Net Profit | 9.42 | 3.99 | 0.49 |
| EPS (₹) | 2.18 | 0.91 | 0.11 |
About Shukra Pharmaceuticals
Shukra Pharmaceuticals is a company that makes and sells pharmaceutical products, including tablets, capsules, and injectable medicines. Established in 1993, it operates with a focus on manufacturing high-quality drugs and conducting laboratory testing.
The company is certified by WHO-GMP, which ensures that its products meet international standards for good manufacturing practices. Shukra Pharmaceuticals also helps other pharmaceutical companies by developing and producing various drugs and dosage forms.
Visit our website for more Q1 results.
Shukra Pharmaceuticals Q1 Results- FAQs
1. What are Shukra Pharmaceuticals' Q1 2024-2025 revenue figures?
Shukra Pharmaceuticals reported revenue from operations of ₹317.80 lakhs for Q1 2024-2025.
2. How much did Shukra Pharmaceuticals earn in net profit for Q1 2024-2025?
Shukra Pharmaceuticals earned a net profit of ₹48.53 lakhs for Q1 2024-2025.
3. What was Shukra Pharmaceuticals' revenue from operations in Q4 2023?
Shukra Pharmaceuticals reported revenue from operations of ₹1,088.39 lakhs in Q4 2023.
4. What was the net profit for Shukra Pharmaceuticals in the previous quarter?
Shukra Pharmaceuticals' net profit in the previous quarter was ₹398.59 lakhs.
5. How much did Shukra Pharmaceuticals' total income from operations decline in Q1 2024-2025?
Shukra Pharmaceuticals' total income from operations declined to ₹389.56 lakhs in Q1 2024-2025.
6. What were the total expenses for Shukra Pharmaceuticals in Q1 2024-2025?
Shukra Pharmaceuticals' total expenses were ₹309.89 lakhs in Q1 2024-2025.
7. What was Shukra Pharmaceuticals' profit before tax in Q1 2024-2025?
Shukra Pharmaceuticals' profit before tax was ₹79.67 lakhs in Q1 2024-2025.
8. How much did Shukra Pharmaceuticals spend on tax expenses in Q1 2024-2025?
Shukra Pharmaceuticals spent ₹26.60 lakhs on tax expenses in Q1 2024-2025.
9. What was Shukra Pharmaceuticals' earnings per share (EPS) in Q1 2024-2025?
Shukra Pharmaceuticals' earnings per share (EPS) was ₹0.11 in Q1 2024-2025.
10. How did Shukra Pharmaceuticals' EPS compare to the previous quarter?
Shukra Pharmaceuticals' EPS was ₹3.64 in the previous quarter.